Last reviewed · How we verify
Erenumab Auto-Injector
Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.
Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. Used for Prevention of migraine in adults.
At a glance
| Generic name | Erenumab Auto-Injector |
|---|---|
| Also known as | Botox, and oral migraine preventives |
| Sponsor | Clinique des Céphalées de Montréal |
| Drug class | monoclonal antibody |
| Target | CGRP receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By binding to the CGRP receptor, erenumab prevents the action of CGRP, a molecule involved in the transmission of pain signals. This mechanism is thought to be effective in treating migraines.
Approved indications
- Prevention of migraine in adults
Common side effects
- Injection site reactions
- Nausea
- Headache
Key clinical trials
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (PHASE4)
- Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erenumab Auto-Injector CI brief — competitive landscape report
- Erenumab Auto-Injector updates RSS · CI watch RSS
- Clinique des Céphalées de Montréal portfolio CI